Havemeyer Place LP Invests $1.33 Million in Globus Medical, Inc. $GMED

Havemeyer Place LP acquired a new position in Globus Medical, Inc. (NYSE:GMED) in the fourth quarter, HoldingsChannel.com reports. The institutional investor acquired 15,204 shares of the medical device company’s stock, valued at approximately $1,327,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Advisory Services Network LLC bought a new position in Globus Medical during the third quarter valued at approximately $26,000. EverSource Wealth Advisors LLC boosted its stake in Globus Medical by 74.3% during the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after buying an additional 197 shares during the last quarter. SBI Securities Co. Ltd. boosted its stake in Globus Medical by 98.2% during the fourth quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock valued at $29,000 after buying an additional 167 shares during the last quarter. Parallel Advisors LLC boosted its stake in Globus Medical by 45.1% during the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock valued at $32,000 after buying an additional 173 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in Globus Medical during the third quarter valued at approximately $36,000. 95.16% of the stock is owned by institutional investors.

Globus Medical Stock Performance

Shares of NYSE GMED opened at $80.13 on Monday. The business’s 50 day moving average price is $86.27 and its 200-day moving average price is $88.25. Globus Medical, Inc. has a fifty-two week low of $51.79 and a fifty-two week high of $101.40. The company has a market cap of $10.88 billion, a price-to-earnings ratio of 18.63, a PEG ratio of 1.65 and a beta of 0.95.

Globus Medical (NYSE:GMED) last issued its quarterly earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share for the quarter, topping the consensus estimate of $0.92 by $0.20. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The firm had revenue of $759.85 million for the quarter, compared to the consensus estimate of $740.35 million. During the same period in the prior year, the business posted $0.68 earnings per share. The company’s revenue for the quarter was up 27.0% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. Sell-side analysts predict that Globus Medical, Inc. will post 4.74 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on GMED. Truist Financial set a $115.00 price target on Globus Medical in a research note on Wednesday, February 25th. Wall Street Zen lowered Globus Medical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Wells Fargo & Company dropped their price target on Globus Medical from $104.00 to $103.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Barclays increased their price target on Globus Medical from $118.00 to $123.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Finally, Zacks Research raised Globus Medical from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 3rd. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, Globus Medical presently has a consensus rating of “Moderate Buy” and a consensus price target of $106.36.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.